Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) was the recipient of a significant increase in short interest in February. As of February 28th, there was short interest totalling 119,700 shares, an increase of 93.4% from the February 13th total of 61,900 shares. Based on an average daily volume of 4,130,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 6.5% of the company’s stock are sold short.

Institutional Trading of Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Renaissance Technologies LLC acquired a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,611 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned about 0.39% of Cyclerion Therapeutics as of its most recent SEC filing. 75.62% of the stock is currently owned by hedge funds and other institutional investors.

Cyclerion Therapeutics Price Performance

CYCN stock traded up $0.06 during mid-day trading on Friday, reaching $2.53. The company had a trading volume of 7,764 shares, compared to its average volume of 2,412,826. The stock has a 50 day simple moving average of $3.05 and a two-hundred day simple moving average of $2.90. The company has a market capitalization of $6.86 million, a price-to-earnings ratio of -2.07 and a beta of 2.09. Cyclerion Therapeutics has a 52 week low of $1.27 and a 52 week high of $9.47.

Cyclerion Therapeutics (NASDAQ:CYCN) last released its quarterly earnings data on Tuesday, March 4th. The company reported $0.22 earnings per share (EPS) for the quarter. The business had revenue of $1.81 million during the quarter.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.